In overweight or obese patients without diabetes mellitus, patients treated with GLP-1 RAs had significantly reduced major adverse cardiovascular events, all-cause death, myocardial infarction, and revascularization when compared with placebo [36] [37] [38]
Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M
Gut microbiota-dependent metabolite trimethylamine n-oxide contributes to cardiac dysfunction in Western diet-induced obese mice
If pregnancy occurs during treatment, the medication should be stopped immediately and healthcare providers notified
Preliminary results: The weight loss rate of the combnation therapy form reached 18.3%, and the muscle mass retention rate was better than that of the monotherapy form, indicating the potential for synergistic effect of multi-target therapy